Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Market Cap	21.43B
Revenue (ttm)	3.07B
Net Income (ttm)	404.52M
Shares Out	418.49M
EPS (ttm)	0.97
PE Ratio	52.77
Forward PE	25.92
Dividend	0.20 (0.39%)
Ex-Dividend Date	Jun 6, 2024

Volume	10,824,301
Average Volume	9,022,158
Open	50.57
Previous Close	49.99
Day's Range	50.57 - 53.96
52-Week Range	30.43 - 59.88
Beta	0.84
RSI	49.15
Earnings Date	Apr 18, 2025

About Betta Pharmaceuticals

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,961
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300558

Financial Performance

In 2024, Betta Pharmaceuticals's revenue was 2.89 billion, an increase of 17.74% compared to the previous year's 2.46 billion. Earnings were 402.57 million, an increase of 15.67%.